Liver disease therapeutics company Ochre Bio has assembled a 10-member scientific strategy board following the close of a $30 million series A funding round.
Ten physician, researcher leaders at Ochre Bio:
1. Sangeeta Bhatia, MD, PhD — Wilson Professor of Engineering at Massachusetts Institute of Technology in Cambridge
2. Chinwe Ukomadu, MD, PhD — Senior vice president and head of GI therapeutics at Takeda
3. Chas Bountra, PhD — Pro vice chancellor for innovation and professor of translational medicine at the University of Oxford (England)
4. Scott Friedman, MD — Professor and chief of the division of liver sciences at Mount Sinai in New York City
5. Troy Dale — Head of the strategic partnerships unit at Novartis
6. Joel Dudley, PhD — Partner at Innovation Endeavors
7. Michael Hodges, MD — RNA therapeutics consultant
8. Leanne Hodson, PhD — Professor of metabolic physiology at the University of Oxford
9. Eduardo Martins, MD, PhD — chief medical officer at Sagimet
10. Alex Shalek, PhD — Core member of the Institute for Medical Engineering and Science
"True to Ochre's philosophy of highly transdisciplinary expertise from technology through to biology, we are honored to have a strong group of advisors who will challenge us to do the best possible science and help us advance our therapies to patients," Quin Wills, PhD, chief scientific officer and co-founder of Ochre Bio, said in an Oct. 20 press release.